Use of low-dose rituximab to treat pemphigus
Open Access
- 15 June 2024
- journal article
- letter
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 99 (5) , 791-792
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Comparison of the efficacy and cost-effectiveness of an immunologically targeted low-dose rituximab protocol with the conventional rheumatoid arthritis protocol in severe pemphigusClinical and Experimental Dermatology, 2022
- Clinical observation of different doses of rituximab for the treatment of severe pemphigus: A single-center prospective cohort studyJournal of the American Academy of Dermatology, 2022
- Ultralow‐dose rituximab in pemphigus: a single‐centre experienceBritish Journal of Dermatology, 2021
- Rituximab: A Review in Pemphigus VulgarisAmerican Journal of Clinical Dermatology, 2019
- First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trialThe Lancet, 2017